ERBB2 and neoplasm: Recruiting is ongoing in a phase III study to evaluate the efficacy and safety of alpelisib compared to placebo in combination with anti-HER2 therapy as maintenance treatment of patients with HER2-positive MBC who present a PIK3CA mutation in tumor (Table 2).